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Objective: To investigate feasibility and safety of 
stereotactic ablative radiotherapy in the management 
of prostate cancer while employing MR/CT fusion 
for delineation, fiducial marker seeds for positioning 
and Varian RapidArc with flattening filter free (FFF) 
delivery.
Methods: 41 patients were treated for low-interme-
diate risk prostate cancer with initial prostate-specific 
antigen of ≤20 ng ml−1, Gleason score 6–7. Patients had 
MR/CT fusion for delineation of prostate ±seminal vesi-
cles. CT/MR fusion images were used for delineation 
and planned using flattening filter free modality. Veri-
fication on treatment was cone beam CT imaging with 
fiducial markers for matching. Patients had Radiation 
Therapy Oncology Group scoring for genitourinary and 
gastointestinal symptoms at baseline, week 4, 10 and 
18.
Results: Clinically acceptable plans were achieved for 
all patients, all plans achieved the objective clinical 
target  volume D99% ≥ 95%, and for planning  target 
volume D95% ≥ 95%. Rectum dose constraints were 
met for 95.1% for V18 Gy ≤ 35%, 80% V28 Gy ≤ 10%. A 
total of 32 (78.0%) plans achieved all rectum dose 
constraints.Grade 1 acute genitourinary symptoms were 
53.7% of patients at baseline, 90.2% [95%  CI  (76.8–
97.3%)] (p = 0.0005) at treatment 5, falling to 
78.0% (62.4–89.4%) at week 4, and 75.0% (58.8–87.3%) 
by week 10 and 52.5% (36.1–68.5%) (p = 1.00) at week 
18.Acute gastrointestinal symptoms were 5% at base-
line, 46.3% [95% CI (30.7–62.6%)] at treatment 5, week 
4 43.9% [95% CI  (28.5–60.3%)], week 10 25.0%  (11.1–
42.3%), and declined slightly by week 18 [–20.095% 
CI (12.7–41.2)] p = 0.039. Overall 75.6% (31/41) of patients 
experienced Grade 1–2 toxicity during or after treatment.
Conclusion: This planning and delivery technique is 
feasible, safe and efficient. A homogeneous dose can 
be delivered to prostate with confidence, whilst limiting 
high dose to nearby structures. The use of this tech-
nology can be applied safely within further randomized 
study protocols.
Advances in knowledge: Multimodality imaging for 
delineation and linac-based image-guided RT with 
FFF for the treatment of prostate stereotactic ablative 
radiotherapy.
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intRODuCtiOn
Prostate cancer is the second most common cancer among 
males in Western Europe.1 In the UK around 47,000 males 
are currently diagnosed each year.2
There are several treatment options for early stage  organ 
confined disease including active surveillance, pros-
tatectomy, external beam radiotherapy (EBRT) and 
brachytherapy.3
EBRT is a non-invasive treatment which delivers poten-
tially curative doses of RT to the target. Conventionally, 
fractionated RT for prostate cancer typically involves doses 
of 74–78 Gy delivered in 37–39 fractions.4–6 A recent trial 
of conventional vs hypofractionated high-dose intensity 
modulated RT for prostate cancer (CHHIP) demonstrated 
that a moderate hypofractionated schedule of 60 Gy in 20 
fractions was non-inferior to commonly used 74 Gy in 37 
fractions. This regime has been recommended as the new 
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standard of care, in which patients can have equivalent treatment 
in fewer hospital visits.7
EBRT is a complex medical intervention with elements of uncer-
tainty resulting from: delineation, inter- and intrafraction motion. 
It is not possible to irradiate the prostate alone, nearby organs are 
at risk of exposure to a high dose. Advances in RT planning and 
delivery have increased the efficiency of the procedure, reducing 
exposure to the nearby organs and surrounding healthy tissues. 
In the UK and Europe, standard gantry-based linear accelerators 
which can deliver intensity modulated RT, image-guided RT  and 
rotational therapy are more readily available.8,9
There is evidence to suggest that prostate cancer has a low α/β 
ratio (1.5 Gy), lower than that of late responding normal tissues. 
Such evidence can be utilized in one of two ways; to deliver larger 
doses to the prostate in fewer fractions, thus improving tumour 
control rates without increasing the risk of late normal tissue 
complications or to deliver isoeffective doses in fewer fractions, 
aiming to reduce late toxicity.10,11
Internationally, hypofractionated stereotactic ablative radio-
therapy (SABR) has become accepted as a therapeutic modality 
in the treatment of organ-confined prostate cancer, not currently 
recommended in the UK.12,13 SABR delivers a higher dose of 
radiation over a smaller number of fractions. These hypofrac-
tionated regimens typically involve a dose of around 35–40 Gy 
delivered in five fractions either daily or on alternate days.14 
Current evidence on toxicity comes from a number of case 
series with some mature data demonstrating outcomes up to 7 
years.15,16
This study aims to contribute to the body of evidence regarding 
the feasibility of using SABR in the management of prostate 
cancer, employing MR/CT fusion for delineation, fiducial 
markers for positioning and Varian RapidArc with flattening 
filter free (FFF) delivery.  Primary end  points for this study 
were:
(1) Can clinically acceptable plans be achieved in 90% of study 
patients using prostate SABR protocol by assessing planning 
target volume (PTV) coverage and specified dose constraints 
for rectum and bladder.
(2) Safety will be demonstrated, if incidence of Radiation 
Therapy Oncology Group (RTOG) grade toxicity of rade ≥3 
occurs in less than 10% of patients.
MethODS AnD MAteRiAlS
This prospective study was approved by the Research Ethics 
Committee on 21 May 2013. Patients in this study provided 
written informed consent.
Patient selection and characteristics
Patients in the study had low- to intermediate-risk prostate 
cancer, i.e. organ-confined disease, initial prostate-specific 
antigen (iPSA) of ≤20 ng ml−1, Gleason score 6–7. All patients 
had histologically proven adenocarcinoma of the prostate. 
Biopsy was obtained using a transrectal approach. All patients 
underwent a staging MRI. Only patients with a PSA ≥10 had 
a bone scan, as per local guidelines. Patients with intermedi-
ate-risk disease received androgen deprivation therapy (ADT) in 
the form of luteinizing hormone-releasing hormone analogues, 
for a period of 6–9 months. RT started 3 months after initiation 
of ADT.
Protocol treatment planning
2 weeks before planning, patients attended seed clinic. A urine 
sample was checked for infection and an enema adminis-
tered. Three gold markers measuring 5 mm (BEBIG gold fidu-
ciary markers, Riverpoint Medical, Portland, OR) were inserted 
into the prostate transrectally using transrectal ultrasound guid-
ance. Intended positions of the seeds were the left superior lobe, 
left apex and right midgland. Ultrasound images were acquired 
and a 5 day course of ciprofloxacin antibiotics was given to 
reduce the risk of infection.
Patients received a microlax enema before the CT simulation 
appointment. Once this had taken effect, patients emptied their 
bladders and drank 450 ml of water 30 min before scanning. 
Patients were scanned using a GE MultisliceLightSpeed™ 16 
helical CT scanner (GE Medical Systems, Waukesha, WI).
Scans were acquired in a  supine position, with head support 
and Prostep immobilization device (ProSTEP™ ABS, MEDIZIN-
TECHNIK GMBH). Slices were reconstructed at 2.5 mm width. 
Orthogonal and anterior tattoos were aligned to the origin of the 
scan to aid daily treatment setup.
MRI scans were acquired on the same day as the planning CT 
on a GE Signa HDxt1.5T (HD23.0_VOL_1210a) (GE Medical 
Systems). Setup was achieved using the immobilization employed 
at CT following the same bladder and bowel preparation. A flat 
couch top was used with a 4-channel cardiac coil. Sequences 
included: Ax 3DGRE*2.5 SEED, axial T2 HiRes −2.5 mm (small 
field of view) 50 slices, check field of view includes the heads of 
femurs and prostate, interleaved, zero spacing. MR and CT scans 
were registered in Eclipse using a mutual information match and 
adjusted manually to ensure the seeds were in alignment.
Delineation
Delineation was performed using the fused MRI/CT image set.
The CTV was taken as the prostate only (or in some circumstances 
prostate + seminal vesicles) as outlined by the clinical oncologist 
(CO). The PTV was taken as CTV with 5 mm margins added in 
all directions except posteriorly (3 mm, to spare as much rectum 
as possible). The organs at risk (OAR), in accordance with the 
SABR Consortium UK guidelines13 were the rectum (from the 
anus to the rectosigmoid junction), the bladder (including wall 
and lumen) and left and right femoral heads.
Planning
Treatments were planned and delivered using volumetric-modu-
lated arc therapy (VMAT) (RapidArc™) on a VarianTruebeamSTx 
linear accelerator using FFF mode.
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Table 1. Patient characteristics
Baseline characteristics 
(n = 41) Median (IQR) or % (n)
Age (years) 68 (65–71)
initial PSA (ng ml–1) 10.5 (8.0–13.3)
T stagea 1 14.6 (6)
2 82.9 (34)
Gleason score 6 41.5 (17)
7 58.5 (24)
Androgen deprivation therapy No 24.4 (10)
Yes 75.6 (31)
aT-stage not recorded for one patient. IQR, interquartile range; PSA, 
prostate-specific antigen.
Table 2. Clinical  and planning treatment volume (cm3) and 
volume of organs at risk
Planning 
characteristics (n = 41) Median volume (IQR) (cm3)
CTV 36.0 (29.9–45.1)
PTV 76.4 (64.8–90.1)
Organs at risk
  Rectum 67.1 (56.4–78.2)
  Bladder 164.4 (120.3–229.2)
  Right femoral head 62.5 (55.1–68.3)
  Left femoral head 61.9 (54.2–68.1)
IQR, interquartile range; CTV, clinical target volume; PTV, planning 
target volume.
Treatment planning was performed in Eclipse External Beam 
Planning system V10.0.39 (Varian Medical Systems, Palo Alto, 
CA).
Plans were optimized using the inverse planning Progressive 
Resolution Optimiser (PRO3) and the final dose calculation was 
performed using Anisotropic Analytical Algorithm AAA 10.0.28 
with a calculation grid size of 1.25 mm.
Intended planning criteria was V95% > 99% for the CTV and 
V95% > 95% for PTV.17 Constraints placed on the OARs were 
rectum; V18 Gy < 35%, V28 Gy < 10%, V32 Gy < 5% and D1% < 
35 Gy and bladder; D1% < 35 Gy. These constraints were based 
on those used by Alongi et al18.
Each plan used two full arcs with a collimator separation 
between the two arcs of 90° degrees. This separation ensures that 
any effect of multileaf collimators (MLCs) leakage is not summed 
throughout both arcs and also gives a greater variety of beam 
orientations around the target volume.
Quality assurance
Verification plans were produced within Eclipse, delivered to the 
SunNuclearMapCHECK 2 phantom. A sagittal plane of interest 
was analysed and agreement criterion was set to 3% dose differ-
ence, 3 mm distance to agreement, threshold of 10%. Agreement 
in at least 95% of dose points is deemed acceptable. All plans 
passed pre-treatment QA checks.
Treatment
Patients were prepared and immobilized as described previously. 
Each fraction was administered with two full arcs on a Truebeam 
STX using 10X FFF and a dose rate of 2400 MUmin−1.
Verification
Verification was performed to allow online correction prior to 
treatment delivery. A CBCT image was acquired on the True-
beam STX (VarianMedicalSystems, Palo Alto, CA). An automatic 
match was performed using PTV as volume of interest. Manual 
adjustments were made to the registration by radiographers to 
ensure seeds aligned correctly. The CO then checked through 
transverse slices to visualize organs at risk, CTV coverage before 
online correction applied.
Follow up
Baseline data was recorded before the first treatment. Patients 
were reviewed before each treatment fraction, then by telephone 
4 weeks after starting treatment. Subsequently, patients were 
reviewed at clinic week 10, 18, 26 and 6 monthly, thereafter. The 
RTOG acute and late toxicity scoring criteria  used to record 
skin, gastrointestinal (GI), genitourinary (GU) toxicity.19 Erec-
tile dysfunction was recorded from week 18 onwards. Routine 
follow up after 18 weeks, collected late toxicity data and assessed 
PSA levels.
Statistical analysis
Grouped dose volume histograms (DVH) were produced 
for prostate and OAR. We report both the number and the 
proportion of patients who reported each grade of toxicity at: 
baseline, each treatment and each follow up. Median and IQRs 
were used to summarize continuous variables. McNemars test 
and exact 95% confidence intervals were used to compare the 
proportion of patients with acute toxicity. Statistical analyses 
performed using StataCorpStata Statistical Software: v. 14.0.
ReSultS
Patient characteristics
41 patients were recruited between 22 November 2013 and 30 
March 2016. Median PSA was 10.5 ng ml−1 (range 4.3–29.9) 
(Table  1).  Three patients recruited had iPSA greater than 20 
due to initial uncertainty over iPSA measurements, these 
patients were retained in our analysis.  The median age was 
68 [interquartile range (IQR) 65–71] years. A total of 24 
(58.5%) patients  had a Gleason score of 7, all other patients 
[17 (41.5%)] were Gleason score 6.  Six patients had Stage 1 
disease, all others were Stage 2 (35 85.4%). Over three quarters 
of patients (31/41) had received ADT. The median initial PSA 
was 10.5 (IQR 8.0–13.3) ng ml−1.
Planning characteristics are shown in Table 2. The median CTV 
and PTV was 36.0 cm3 (IQR 29.9–45.1) and 76.4 cm3 (IQR 
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Table 3. Planning objectives and number (%) of plans achieving these
Organ Planning objective or constraint
Median volume (IQR) 
(%) Range
Number of plans meeting 
objective (%)
CTV V95% > 99% 100 (100.0–100.0) 99.8–100.0 41 (100)
PTV V95% > 95% 96.3 (95.4–97.0) 95.0–99.6 41 (100)
1 cm3 < 107% 38 (92.7)
Rectum
  
V18 < 35% 26.9 (22.6–31.2) 11.9–42.0 39 (95.1)
V28 < 10% 7.7 (6.2–9.3) 1.3–22.5 33 (80.5)
V32 < 5% 3.7 (2.6–4.6) 0.2–14.8 34 (82.9)
V35 < 1% 0.2 (0.0–0.6) 0.0–2.4 38 (92.7)
Bladder V35 < 1% 0.1 (0.0–0.6) 0.0–3.0 34 (82.9)
64.8–90.1) respectively. The median PTV was approximately two 
times the median CTV.
Table  3 shows planning objectives and proportion of plans 
achieving these. All plans achieved the objective that 99% of 
the CTV should receive at least 95% dose, and that 95% of the 
PTV should receive at least 95% prescribed dose. The proportion 
of plans meeting rectum dose constraints ranged from 95.1% 
(39/41) for the relative volume receiving 18  Gy (V18) being 
less than 35%, to just over 80% (33/41) for the relative volume 
receiving 28 Gy (V28) being less than 10%. Overall a total of 32 
(78.0%) plans achieved all rectum dose constraints. One plan 
failed to achieve all rectum dose constraints. Constraints on the 
dose received by the bladder were met by 34 plans, the propor-
tion of bladder receiving >35% of the dose ranged from 0 to 3.0%.
Figure  1 shows the median cumulative DVH for all patients 
and each structure  highlighting the IQR and minimum and 
maximum volume at each point dose. The figure shows very 
small variation between plans for doses received by CTV and 
PTV. The plots for rectum and bladder show large variation in 
the volume receiving each point dose. Femoral heads show rapid 
decline in the dose received.
Table 4 summaries the dose received by the CTV and PTV in 
more detail.
The proportion of patients who reported acute genitouri-
nary (GU) and GI toxicity during and after treatment are shown 
in Figures 2 and 3. Grade 1 acute GU symptoms were prevalent 
among 53.7% of patients (22/41) at baseline. The percentage 
of patients who experienced any symptoms increased during 
treatment and peaked at 90.2% [95% CI (76.8–97.3%)] (37/41) 
(p = 0.0005) at treatment 5. The prevalence of symptoms 
declined slowly thereafter, falling to 78.0% (62.4–89.4%) at 
week 4, and 75.0% (58.8–87.3%) by week 10. At 18 weeks, two 
patients continued to experience Grade 2 symptoms, but the 
overall percentage of patients with symptoms had returned 
to baseline levels– 52.5% (36.1–68.5%) (p = 1.00). All patients 
reported Grade 1 or worse GU symptoms, of which 46.9 (18/41) 
did not report symptoms at baseline. The proportion of patients 
reporting Grade 2 or worse was 14 of 41 (34.1%). Only two 
patients experienced Grade 3 symptoms (4.9%).
Five percent (2/41) of patients reported acute GI symptoms 
at baseline. These increased during treatment, reported by 
46.3% [95% CI (30.7–62.6%)] of patients at treatment 5. GI 
symptoms  continued to be raised at week 4 in  43.9% (95% CI 
28.5–60.3%). GI side effects were lower at week 10 [25.0% 
(11.1–42.3%)], and declined slightly by week 18 [−20.095% CI 
(12.7–41.2)] p = 0.039. Acute Grade 2 GI toxicity was experi-
enced by three patients (7.3%). No patients experienced Grade 3 
GI toxicity. Overall, 75.6% (31/41) of patients experienced Grade 
1–2 toxicity during or after treatment.
At baseline, the median PSA was 10.5 (IQR 8.0–13.3). By 
week 18, the median PSA was 0.6 (IQR 0.2–1.1). A total of 
24 patients (68.6%) had a PSA <1, 17.1% had a PSA between 
1 and  ≤ 2, and 14.3% had  PSA levels between 2 and  ≤ 4 
(Figure 4).
DiSCuSSiOn
This is the first UK study to show SABR of low-intermediate 
risk prostate cancer with FFF is feasible and safe. It is also the 
first prospective study reporting on this method of planning 
and delivery using CT/MR fusion, fiducials and CBCT.  While 
a number of studies have described patient outcomes for pros-
tate cancer who received SABR, there is a lack of randomized 
study  evidence to support its use as the standard of care. In 
this analysis, treatment plans were assessed as clinically accept-
able for all patients. Assessment of acute side effects among 
patients receiving SABR for prostate cancer with a median 
follow-up of 18 weeks showed that this treatment is well- 
tolerated.
Reported outcomes were similar to those in the CHHIP trial, 
where GU toxicity in hypofractionated arm peaks at week 5 
which is 1 week after end of treatment. Acute GU toxicity in our 
study peaked earlier than CHHIP trial with the highest incidence 
of toxicity being noted at fraction 5, i.e. at the end of treatment. 
This reduced slightly at week 4, dropping to near baseline at week 
18. GI toxicity peaked at week 4, same as CHHIP and although 
Grade 2 returned to 0 by week 18, Grade 1 toxicity was still 
reported.7 Acute side effects described were acceptable and are 
consistent with other studies.15,16,18 PSA levels were reduced in 
all patients.
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Figure 1. Median cumulative dose volume histograms for each organ highlighting the range and interquartile range at each dose.
Table 4. Summary of the dose received by clinical and planning treatment volumes
Planning 
characteristics 
(n = 41)
Dose (%) received 
by 99% of volume 
(D99%)
Dose (%) 
received by 1 
cm3
Volume (%) 
receiving ≥ 95% 
of dose (V95%)
Volume (%) 
receiving ≥ 105% 
of dose (V105%)
Volume (%) 
receiving ≥ 107% 
of dose (V107%)
CTV 98.6 (96.8–101.0) 105.2 (102.8–106.9) 100 (99.8–100.0) 4.4 (0–47.2) 0.0 (0.0–2.0)
PTV 91.5 (86.6–95.6) 105.7 (103.4–107.1) 96.3 (95.0–99.6) 4.5 (0–31.5) 0.0 (0.0–1.5)
Numbers are medians and range. CTV, clinical target volume; PTV, planning target volume.
The dose used within this study was 35 Gy delivered in five frac-
tions on alternate days. This has been reported elsewhere and 
results have shown good biochemical recurrence free survival 
(BRFS) in low-intermediate group. Katz et al15 reported 7 years 
being 95.6% for low-risk and 89.6% for intermediate risk, also 
indicating there was no difference in biochemical disease free 
survival (bDFS) between delivering 35 and 36.25 Gy. Our patients 
were treated on alternate days, taking a total of 11 days to deliver 
the full course. This was  selected to allow recovery of normal 
tissue between fractions.20 Previous reports have suggested daily 
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Figure 2. Acute GU toxicity (RTOG criteria).  GU,  genitouri-
nary; RTOG, Radiation Therapy Oncology Group.
Figure 3. Acute GI toxicity (RTOG criteria). GI, genitourinary; 
RTOG, Radiation Therapy Oncology Group.
Figure 4. Distribution of PSA levels at baseline and at week 
18. PSA, prostate-specific antigen.
treatment increased toxicity, however this has since been chal-
lenged, with dose being a more relevant predictor of late effects.15 
Disease control is not covered in this paper as those data are not 
mature enough to present.
The treatment modality used was 10X FFF. This is a relatively 
new modality which delivers the beam without the use of a flat-
tening filter. Delivery using this technique allows a much higher 
dose delivery per pulse which results in an accelerated delivery 
of around 2400 MU min-1, around four times faster than with 
filter. Thus, enabling a dose of 700 cGy to be delivered in around 
2 min per fraction, limiting time intrafraction movement  can 
occur. FFF technology also offers potential for a reduction in out 
of field dose due to reduced head scatter and reduced residual 
electron contamination.20,21
Equivalent dose of RT using Cyberknife would take around 
45 min. Although tracking of the target volume is intermittent 
throughout, the patient has to lie in the treatment position for 
a significantly longer duration.20,21 There are fewer publica-
tions using linac-based delivery systems, mostly reported using 
routine equipment with MV imaging.22–24
TruebeamSTx is Varian Medical Systems newest platform of 
linear accelerator. This model offers a new high-definition MLC 
system, which has a reduced individual leaf width of 2.5 mm. All 
plans developed for this study utilized this MLC system.
Cumulative DVHs demonstrate that prescribed planned dose 
to CTV and PTV was achieved for all patients. A homogeneous 
dose achieved, with little variation between patients. Rectum 
and bladder constraints show more interpatient variability. 
This is due to the variation in; organ volume, location and the 
limited number of constraints applied. Possibly, by applying 
further constraints, this variation could be reduced. Unlike other 
anatomical sites, where dose would be prescribed to an isodose 
line, it is beneficial for the prostate to receive a uniform dose, 
prescribed to the volume. Where patients failed to meet one or 
more rectal constraints, further investigation suggested overlap 
with PTV was the cause of this. In this study, PTV had priority 
over OAR.
Pre-treatment QA checks were performed on each study plan 
to ensure the planned treatment could be delivered accurately. 
Satisfactory results from this study have confirmed, it is not 
necessary to undertake any further, extensive testing for such 
plans. Future prostate SABR treatments will be verified in accor-
dance with routine departmental protocol.
PACE international randomized study is ongoing and will 
compare laparoscopic prostatectomy, SABR and conventionally 
fractionated RT. This will address the current lack of randomized 
evidence by comparing SABR to conventional treatment or SABR 
to surgery.25 This study previously mandated MR for improved 
delineation. However, PACE study data using MR/CT fusion to 
delineate the prostate gland has been presented to support the 
use of CT only delineation in recent versions of the protocol. This 
change will allow centres with limited MR resource to recruit to 
the study.26 When CTV is compared to evidence, the volumes 
among our patients were on average approximately 30% smaller 
than those in the studies by Henderson and Alongi, suggesting 
the use of MR/CT fusion significantly reduces the size of the 
CTV.14,18 It is known that soft tissue delineation of the prostate 
using MR is optimal due to the enhanced soft tissue contrast and 
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that volumes on MR are smaller than on CT.27,28 Fiducial markers 
are essential  to allow accurate fusion of the MR and CT, mini-
mizing fusion error. A publication by D’Agostino reported on a 
similar planning methodology, however, no CT/MR fusion was 
described, only MR-assisted delineation.
Patients in our study had CBCT and fiducial markers before 
treatment allowing all setup corrections to be made. We found it 
necessary to use both methods to ensure the prostate was aligned 
to that of the planning CT at each session and visually assess 
rectum and bladder displacement/volume change. Three-dimen-
sional information gave gross indication of the high dose region 
in relation to OAR and PTV. Online images were approved by a 
CO, with appropriate training, in our opinion this could become 
a radiographer led process. Alongi  et al18 described the use of 
three-dimensional CBCT prior to each treatment to aid setup. 
This was performed without complementary use of fiducial 
markers in the prostate. Following on from this, a subsequent 
publication by the same group included a further 50 patients. 
Again, fiducials were not mandated and no indication is given to 
how many patients had them inserted, meaning accurate fusion 
of MR/CT would not have been possible. They also described an 
alternative method of online verification, where no correction for 
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in our centre, where there is a large geographical catchment area. 
There are also potential opportunities to reduce burden on RT 
services where capacity issues exist.
COnCluSiOn
This prospective prostate  SABR study, using multimodality 
imaging for delineation and volumetric arc RT with FFF demon-
strates safety and feasibility for this group of patients. This adds 
to the body of evidence on choosing the optimal RT technique, 
achieving a homogeneous dose to the prostate and margin, whilst 
limiting  high dose to nearby structures. It also confirms, it is 
possible to implement a stereotactic setup with FFF beam to 
safely deliver a highly conformal dose to the prostate with confi-
dence. The use of this new technology can be applied safely 
within further randomized study protocols.
ACknOwleDgeMentS
Thank you to the Beatson staff, who contributed to the imple-
mentation and conduct of this study including therapy radiog-
rapher team, MRI radiographers, imaging radiographer Linda 
MacLaren, clinical physics clinical oncologists and clinical nurse 
specialists.
FunDing
This work was supported by the We Can Development Fund, a 
CRUK grant to encourage collaborative working (C596/A12797). 
Research radiographer time was funded by the Beatson Cancer 
Charity.
8 of 8 birpublications.org/bjr Br J Radiol;91:20170625
BJR  Duffton et al
 12.  American Society Radiation Oncology 
(ASTRO). Model policies stereotactic body 
radiation therapy (SBRT); 2013.
 13.  SABR UK Consortium. Stereotactic ablative 
body radiation therapy (SABR): a resource. 
2016. Available from: h ttp: //w ww.actio 
nradioth erapy .or g/wp -con tent /upl oads /201 
6/02/ U KSABRConsortiumGuidelinesv51. 
pdf
 14. Henderson DR, Tree AC, van As NJ. 
Stereotactic body radiotherapy for prostate 
cancer. Clin Oncol 2015; 27: 270–9. doi: 
https:// doi. org/ 10. 1016/ j. clon. 2015. 01. 011
 15. Katz AJ, Kang J. Quality of life and toxicity 
after SBRT for organ-confined prostate 
cancer, a 7-year study. Front Oncol 2014; 4: 
301. doi: https:// doi. org/ 10. 3389/ fonc. 2014. 
00301
 16. Mantz CA, Fernandez E. Real-time target 
tracking prostate SBRT and the real-time 
tracking system 4D localization system: 
5-year quality of life and disease outcomes. 
Int J Radiat Oncol Biol Phys 2013; 87(Suppl 
2): S393. doi: https:// doi. org/ 10. 1016/ j. ijrobp. 
2013. 06. 1030
 17.  ICRU. Prescribing, recording and reporting 
photon beam therapy. Report No: 62. 
Bethesda, MD: International Commission on 
Radiation Units & Measurements, Inc; 1999.
 18. Alongi F, Cozzi L, Arcangeli S, Iftode C, 
Comito T, Villa E, et al. Linac based SBRT 
for prostate cancer in 5 fractions with VMAT 
and flattening filter free beams: preliminary 
report of a phase II study. Radiat Oncol 2013; 
8: 171. doi: https:// doi. org/ 10. 1186/ 1748- 
717X- 8- 171
 19.  RTOG. Adverse Event and Safety 
Information. 2018. Available from: https://
www.rtog.o rg/R esea rchA ssoc iate s/Ad vers 
eEve ntRe por ting/ RTOGEORTCLate Radi atio 
nMor bidi tySco ringSchema. aspx
 20. King CR, Brooks JD, Gill H, Presti JC. Long-
term outcomes from a prospective trial of 
stereotactic body radiotherapy for low-risk 
prostate cancer. Int J Radiat Oncol Biol Phys 
2012; 82: 877–82. doi: https:// doi. org/ 10. 
1016/ j. ijrobp. 2010. 11. 054
 21. King CR, Brooks JD, Gill H, Pawlicki T, 
Cotrutz C, Presti JC. Stereotactic body 
radiotherapy for localized prostate cancer: 
interim results of a prospective phase II 
clinical trial. Int J Radiat Oncol Biol Phys 
2009; 73: 1043–8. doi: https:// doi. org/ 10. 
1016/ j. ijrobp. 2008. 05. 059
 22. Kry SF, Titt U, Pönisch F, Vassiliev ON, 
Salehpour M, Gillin M, et al. Reduced 
neutron production through use of a 
flattening-filter-free accelerator. Int J Radiat 
Oncol Biol Phys 2007; 68: 1260–4. doi: 
https:// doi. org/ 10. 1016/ j. ijrobp. 2007. 04. 002
 23. Scorsetti M, Alongi F, Castiglioni S,  
Clivio A, Fogliata A, Lobefalo F, et al. 
Feasibility and early clinical assessment of 
flattening filter free (FFF) based stereotactic 
body radiotherapy (SBRT) treatments. Radiat 
Oncol 2011; 6: 113. doi: https:// doi. org/ 10. 
1186/ 1748- 717X- 6- 113
 24. Loblaw A, Cheung P, D’Alimonte L, Deabreu 
A, Mamedov A, Zhang L, et al. Prostate 
stereotactic ablative body radiotherapy 
using a standard linear accelerator: toxicity, 
biochemical, and pathological outcomes. 
Radiother Oncol 2013; 107: 153–8. doi: 
https:// doi. org/ 10. 1016/ j. radonc. 2013. 03. 
022
 25. Tree A, Ostler P, van As N. New horizons and 
hurdles for UK radiotherapy: can prostate 
stereotactic body radiotherapy show the way? 
Clin Oncol 2014; 26: 1–3. doi: https:// doi. org/ 
10. 1016/ j. clon. 2013. 11. 002
 26. Henderson DR, Tree AC, van As NJ. 
Stereotactic body radiotherapy for  
prostate cancer. Clin Oncol 2015; 27: 270–9. 
doi: https:// doi. org/ 10. 1016/ j. clon. 2015. 01. 
011
 27. Rasch C, Barillot I, Remeijer P, Touw A, 
van Herk M, Lebesque JV. Definition of the 
prostate in CT and MRI: a multi-observer 
study. Int J Radiat Oncol Biol Phys 1999; 43: 
57–66. doi: https:// doi. org/ 10. 1016/ S0360- 
3016(98)00351-4
 28. Hanvey S, Sadozye AH, McJury M,  
Glegg M, Foster J. The influence of MRI scan 
position on image registration accuracy, 
target delineation and calculated dose in 
prostatic radiotherapy. Br J Radiol 2012; 85: 
e1256–e1262. doi: https:// doi. org/ 10. 1259/ 
bjr/ 26802977
 29. D'Agostino G, Franzese C, De Rose F, 
Franceschini D, Comito T, Villa E, et al. 
High-quality linac-based stereotactic body 
radiation therapy with flattening filter free 
beams and volumetric modulated arc  
therapy for low-intermediate risk prostate 
cancer. A mono-institutional experience with 
90 patients. Clin Oncol 2016; 28: e173–e178. 
doi: https:// doi. org/ 10. 1016/ j. clon. 2016. 06. 
013
